If validated prospectively, the novel immunohistochemistry panel where the role of EGFR-ASAP1 signaling was confirmed in individual tumor cells offers the potential for individualized risk-stratification of each HBL tumor. This evidence concerns the gene EGFR and hepatoblastoma.